Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme

  1. Ruilope, L.M.
  2. Redón, J.
  3. Schmieder, R.
Revista:
Vascular Health and Risk Management

ISSN: 1176-6344

Ano de publicación: 2007

Volume: 3

Número: 1

Páxinas: 1-9

Tipo: Revisión

GOOGLE SCHOLAR
Fonte de datos: Scopus